Information  X 
Enter a valid email address

Company Name matching 'Nyxoah'

Date
Time Source
Company
Announcement
10 Jun 2021 10:46 pm GNW   Nyxoah Nyxoah Issues First Quarter 2021 Results
  10:41 pm GNW   Nyxoah Nyxoah files Registration Statement for Proposed Initial Public Offering in the United States
07 Jun 2021 6:00 am GNW   Nyxoah Nyxoah BETTER SLEEP Trial Reaches its Primary Endpoints
26 May 2021 6:25 pm GNW   Nyxoah Publication relating to a transparency notification
07 May 2021 6:00 am GNW   Nyxoah Invitation to attend the annual shareholders’ meeting of the Company to be held on 9 June 2021
19 Apr 2021 6:02 am GNW   Nyxoah Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States
09 Apr 2021 5:57 am GNW   Nyxoah Nyxoah Reports Full Year 2020 Results
02 Apr 2021 6:02 am GNW   Nyxoah Nyxoah to Delay Full Year 2020 Earnings Release Until April 9, 2021  
03 Mar 2021 5:58 am GNW   Nyxoah Nyxoah announces the publication of first positive clinical data in an OSA patient suffering from Complete Concentric Collapse (CCC)
25 Feb 2021 5:00 pm GNW   Nyxoah Information on the total number of voting rights and shares
24 Feb 2021 6:01 am GNW   Nyxoah Nyxoah to present at the Oppenheimer 31st Annual Healthcare Conference
09 Feb 2021 6:00 am GNW   Nyxoah Nyxoah receives FDA approval for full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)
02 Feb 2021 5:56 am GNW   Nyxoah Nyxoah and Vanderbilt University enter exclusive licensing agreement regarding next generation neurostimulation technologies to treat Obstructive Sleep Apnea (OSA)
26 Jan 2021 6:02 am GNW   Nyxoah Nyxoah announces full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)
05 Jan 2021 6:39 am GNW   Nyxoah First US patient implanted in the DREAM pivotal IDE study, with the Genio® system for the treatment of Obstructive Sleep Apnea (OSA)
20 Nov 2020 6:24 am GNW   Nyxoah Nyxoah to Participate in Annual Piper Sandler Healthcare Conference
17 Nov 2020 6:00 am GNW   Nyxoah First Patient Implanted in the DREAM US Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea (OSA)
25 Sep 2020 6:00 am GNW   Nyxoah Nyxoah announces the end of the Stabilisation Period and the Full Exercise of the Over-allotment Option
18 Sep 2020 6:00 am GNW   Nyxoah Nyxoah Announces Commencement of Trading of Shares on Euronext Brussels
17 Sep 2020 1:41 pm GNW   Nyxoah Nyxoah Raises up to €85 million (US$100m) in Successful Initial Public Offering
14 Sep 2020 5:38 pm GNW   Nyxoah Nyxoah Initial Public Offering Multiple Times Over Subscribed and Early Closing Announced
09 Sep 2020 6:00 am GNW   Nyxoah Nyxoah launches its Initial Public Offering on Euronext Brussels
27 Aug 2020 6:00 am GNW   Nyxoah Nyxoah Announces Intention to Launch an Initial Public Offering on Euronext Brussels
25 Jun 2020 7:00 am GNW   Nyxoah Nyxoah receives IDE approval from the U.S. Food and Drug Administration (FDA) for its DREAM study
09 Mar 2020 7:00 am GNW   Nyxoah Successful first implantation of two patients in Benelux with the Genio® system, a novel Obstructive Sleep Apnea solution by Nyxoah
12 Feb 2020 10:36 pm GNW   Nyxoah Nyxoah raises €25 million in private funding round
27 Nov 2019 7:00 am GNW   Nyxoah Nyxoah announces data demonstrating the benefits and safety of its Genio® system implantation technique for the treatment of Obstructive Sleep Apnea published in Laryngoscope Investigative Otolaryngology
28 Oct 2019 7:00 am GNW   Nyxoah Nyxoah publishes positive Obstructive Sleep Apnea data from BLAST OSA study in the European Respiratory Journal


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t